COVID-19: Implications for People with Chagas Disease

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorZAIDEL, Ezequiel Jose
dc.contributor.authorFORSYTH, Colin J.
dc.contributor.authorNOVICK, Gabriel
dc.contributor.authorMARCUS, Rachel
dc.contributor.authorRIBEIRO, Antonio Luiz P.
dc.contributor.authorPINAZO, Maria-Jesus
dc.contributor.authorMORILLO, Carlos A.
dc.contributor.authorECHEVERRIA, Luis Eduardo
dc.contributor.authorSHIKANAI-YASUDA, Maria Aparecida
dc.contributor.authorBUEKENS, Pierre
dc.contributor.authorPEREL, Pablo
dc.contributor.authorMEYMANDI, Sheba K.
dc.contributor.authorRALSTON, Kate
dc.contributor.authorPINTO, Fausto
dc.contributor.authorSOSA-ESTANI, Sergio
dc.date.accessioned2021-02-18T13:30:29Z
dc.date.available2021-02-18T13:30:29Z
dc.date.issued2020
dc.description.abstractAs the global COVID-19 pandemic advances, it increasingly impacts those vulnerable populations who already bear a heavy burden of neglected tropical disease. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastro-intestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19's potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipFAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/50273-0]
dc.description.sponsorshipCNPqNational Council for Scientific and Technological Development (CNPq) [310679/2016-8, 465518/2014-1]
dc.description.sponsorshipFAPEMIGMinas Gerais State Research Foundation (FAPEMIG) [PPM-00428-17]
dc.identifier.citationGLOBAL HEART, v.15, n.1, article ID 69, 15p, 2020
dc.identifier.doi10.5334/gh.891
dc.identifier.eissn2211-8179
dc.identifier.issn2211-8160
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/39232
dc.language.isoeng
dc.publisherUBIQUITY PRESS LTDeng
dc.relation.ispartofGlobal Heart
dc.rightsopenAccesseng
dc.rights.holderCopyright UBIQUITY PRESS LTDeng
dc.subjectCOVID-19eng
dc.subjectChagas Diseaseeng
dc.subjectNeglected Tropical Diseaseeng
dc.subject.othertrypanosoma-cruzieng
dc.subject.othercongenital transmissioneng
dc.subject.otherindeterminate formeng
dc.subject.otherdrug-interactionseng
dc.subject.otheryoung-womeneng
dc.subject.othermanagementeng
dc.subject.othercyclosporineeng
dc.subject.otherpreventioneng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.titleCOVID-19: Implications for People with Chagas Diseaseeng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countrySuíça
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryColômbia
hcfmusp.affiliation.countryArgentina
hcfmusp.affiliation.countryisoar
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisoes
hcfmusp.affiliation.countryisoca
hcfmusp.affiliation.countryisoco
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisoch
hcfmusp.affiliation.countryisopt
hcfmusp.author.externalZAIDEL, Ezequiel Jose:Sanatorio Guemes Hosp Privado, Buenos Aires, DF, Argentina; Univ Buenos Aires, Sch Med, Pharmacol Dept, Buenos Aires, DF, Argentina
hcfmusp.author.externalFORSYTH, Colin J.:Drugs Neglected Dis Initiat Latin Amer, Rio De Janeiro, Brazil
hcfmusp.author.externalNOVICK, Gabriel:Swiss Med Grp, Buenos Aires, DF, Argentina; Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA
hcfmusp.author.externalMARCUS, Rachel:Latin Amer Soc Chagas, Washington, DC USA
hcfmusp.author.externalRIBEIRO, Antonio Luiz P.:Fed Univ Minas Gerais UFMG, Sch Med, Internal Med Dept, Belo Horizonte, MG, Brazil; Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil
hcfmusp.author.externalPINAZO, Maria-Jesus:Univ Barcelona, ISGlobal, Hosp Clin, Barcelona, Spain
hcfmusp.author.externalMORILLO, Carlos A.:Univ Calgary, Libin Cardiovasc Inst, Calgary, AB, Canada
hcfmusp.author.externalECHEVERRIA, Luis Eduardo:Cardiovasc Fdn Colombia, Dept Cardiol, Floriblanca, Colombia
hcfmusp.author.externalBUEKENS, Pierre:Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA
hcfmusp.author.externalPEREL, Pablo:World Heart Federat, Geneva, Switzerland; London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England
hcfmusp.author.externalMEYMANDI, Sheba K.:Olive View UCLA Med Ctr, Ctr Excellence Chagas Dis, 14445 Olive View Dr, Sylmar, CA 91342 USA
hcfmusp.author.externalRALSTON, Kate:World Heart Federat, Geneva, Switzerland
hcfmusp.author.externalPINTO, Fausto:World Heart Federat, Geneva, Switzerland; Univ Lisbon, Lisbon Sch Med, Dept Cardiol, CCUL, Lisbon, Portugal
hcfmusp.author.externalSOSA-ESTANI, Sergio:Drugs Neglected Dis Initiat Latin Amer, Rio De Janeiro, Brazil; CIESP CONICET, Epidemiol & Publ Hlth Res Ctr, Buenos Aires, DF, Argentina
hcfmusp.citation.scopus39
hcfmusp.contributor.author-fmusphcMARIA APARECIDA SHIKANAI YASUDA
hcfmusp.description.articlenumber69
hcfmusp.description.issue1
hcfmusp.description.volume15
hcfmusp.origemWOS
hcfmusp.origem.pubmed33150134
hcfmusp.origem.scopus2-s2.0-85095677626
hcfmusp.origem.wosWOS:000592723900068
hcfmusp.publisher.cityLONDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAlvar J, 2020, SEMIN IMMUNOPATHOL, V42, P231, DOI 10.1007/s00281-020-00796-yeng
hcfmusp.relation.reference[Anonymous], 2015, Wkly Epidemiol Rec, V90, P33eng
hcfmusp.relation.referenceBaqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0eng
hcfmusp.relation.referenceBarros ML, 2011, REV SOC BRAS MED TRO, V44, P213, DOI 10.1590/s0037-86822011005000020eng
hcfmusp.relation.referenceBatista A, 2020, 1 NOISeng
hcfmusp.relation.referenceBenziger CP, 2017, CARDIOL CLIN, V35, P31, DOI 10.1016/j.ccl.2016.08.013eng
hcfmusp.relation.referenceBern C, 2007, JAMA-J AM MED ASSOC, V298, P2171, DOI 10.1001/jama.298.18.2171eng
hcfmusp.relation.referenceBikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031eng
hcfmusp.relation.referenceBuekens P, 2020, LANCET GLOB HEALTH, V8, pE877, DOI 10.1016/S2214-109X(20)30206-0eng
hcfmusp.relation.referenceCampana C, 1996, CLIN PHARMACOKINET, V30, P141, DOI 10.2165/00003088-199630020-00004eng
hcfmusp.relation.referenceCarlier Y, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007694eng
hcfmusp.relation.referenceCenters for Disease Control, PROV DEATH COUNTS COeng
hcfmusp.relation.referenceChakraborty Abhijit, 2012, Clin Pharmacokinet, V51, pe1, DOI 10.2165/11599820-000000000-00000eng
hcfmusp.relation.referenceChen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078eng
hcfmusp.relation.referenceAlves RMD, 2009, REV SOC BRAS MED TRO, V42, P622, DOI 10.1590/S0037-86822009000600002eng
hcfmusp.relation.referencede Araujo FF, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00663-weng
hcfmusp.relation.referenceSantos-Neto Leopoldo Luiz dos, 2003, Rev. Soc. Bras. Med. Trop., V36, P613, DOI 10.1590/S0037-86822003000500012eng
hcfmusp.relation.referenceDutra WO, 2014, PARASITE IMMUNOL, V36, P377, DOI 10.1111/pim.12107eng
hcfmusp.relation.referenceEcheverria LE, 2020, GLOB HEART, V15, DOI 10.5334/gh.484eng
hcfmusp.relation.referenceFabbro DL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003312eng
hcfmusp.relation.referenceForsyth CJ, 2016, CLIN INFECT DIS, V63, P1056, DOI 10.1093/cid/ciw477eng
hcfmusp.relation.referenceCianciulli TF, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0457-2019eng
hcfmusp.relation.referenceFurtado RG, 2015, ARQ BRAS CARDIOL, V104, P209, DOI 10.5935/abc.20140197eng
hcfmusp.relation.referenceGosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7eng
hcfmusp.relation.referenceGuzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106eng
hcfmusp.relation.referenceHoward EJ, 2014, BJOG-INT J OBSTET GY, V121, P22, DOI 10.1111/1471-0528.12396eng
hcfmusp.relation.referenceImam Z, 2020, J INTERN MED, V288, P469, DOI 10.1111/joim.13119eng
hcfmusp.relation.referenceJackson Y, 2012, TROP MED INT HEALTH, V17, P595, DOI 10.1111/j.1365-3156.2012.02965.xeng
hcfmusp.relation.referenceJanssen Biotech, FULL PRESCR INF 2014eng
hcfmusp.relation.referenceJanssen Pharmaceutical Companies, 2019, PREZCOBIX DAR COB TAeng
hcfmusp.relation.referenceJin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926eng
hcfmusp.relation.referenceKaplinski M, 2015, CLIN INFECT DIS, V61, P918, DOI 10.1093/cid/civ446eng
hcfmusp.relation.referenceKeating SM, 2015, INT J CARDIOL, V199, P451, DOI 10.1016/j.ijcard.2015.07.040eng
hcfmusp.relation.referenceLi B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9eng
hcfmusp.relation.referenceLibby P, 2020, JACC-BASIC TRANSL SC, V5, P537, DOI 10.1016/j.jacbts.2020.04.001eng
hcfmusp.relation.referenceLill J, 2000, AM J HEALTH-SYST PH, V57, P1579, DOI 10.1093/ajhp/57.17.1579eng
hcfmusp.relation.referenceLima-Costa MF, 2010, INT J CARDIOL, V145, P362, DOI 10.1016/j.ijcard.2010.02.036eng
hcfmusp.relation.referenceLin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013eng
hcfmusp.relation.referenceLopez L, 2006, REV ESP CARDIOL, V59, P50, DOI 10.1157/13083649eng
hcfmusp.relation.referenceManne-Goehler J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005033eng
hcfmusp.relation.referenceMartins-Melo FR, 2014, ACTA TROP, V130, P167, DOI 10.1016/j.actatropica.2013.10.002eng
hcfmusp.relation.referenceMilazzo L, 2013, EUR J CLIN PHARMACOL, V69, P743, DOI 10.1007/s00228-012-1397-0eng
hcfmusp.relation.referenceMoccia F, 2020, GEROSCIENCE, V42, P1021, DOI 10.1007/s11357-020-00198-weng
hcfmusp.relation.referenceMontalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921eng
hcfmusp.relation.referenceMustafa NM, 2020, J CLIN VIROL, V128eng
hcfmusp.relation.referenceNath A, 2020, NEUROLOGY, V94, P809, DOI 10.1212/WNL.0000000000009455eng
hcfmusp.relation.referenceNovartis Pharmaceuticals Corporation, 2012, ILARIS CAN FULL PRESeng
hcfmusp.relation.referenceNunes MCP, 2018, EUR HEART J-CARD IMG, V19, P459, DOI 10.1093/ehjci/jex154eng
hcfmusp.relation.referenceOliveira Junior LR, 2018, AME MED J, DOI [10.21037/amj.2018.07.01, DOI 10.21037/AMJ.2018.07.01]eng
hcfmusp.relation.referenceOnder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683eng
hcfmusp.relation.referenceOudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.xeng
hcfmusp.relation.referencePan American Health Organization, 2019, GUID DIAGN TREATM CHeng
hcfmusp.relation.referenceParanjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001eng
hcfmusp.relation.referencePatheon Italia, 2018, GAMIFANTTM EM LZSG Ieng
hcfmusp.relation.referenceNunes MCP, 2018, CIRCULATION, V138, pE169, DOI 10.1161/CIR.0000000000000599eng
hcfmusp.relation.referencePessoa-Amorim G, 2020, EUR HEART J-QUAL CAR, V6, P210, DOI 10.1093/ehjqcco/qcaa046eng
hcfmusp.relation.referencePfizer Inc, 2017, RAPAMUNEeng
hcfmusp.relation.referencePinazo M.J., 2016, PLOS NEGLECT TROP D, V10, P1, DOI 10.1371/J0URNAL.PNTD.0004269eng
hcfmusp.relation.referencePinazo MJ, 2010, ANTIMICROB AGENTS CH, V54, P4896, DOI 10.1128/AAC.00537-10eng
hcfmusp.relation.referenceRassi A, 1999, Rev Soc Bras Med Trop, V32, P475, DOI 10.1590/S0037-86821999000500002eng
hcfmusp.relation.referenceRassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-Xeng
hcfmusp.relation.referenceRegueiro A, 2013, INT J CARDIOL, V165, P107, DOI 10.1016/j.ijcard.2011.07.089eng
hcfmusp.relation.referenceReza N, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.120.007219eng
hcfmusp.relation.referenceRibeiro AL, 2012, NAT REV CARDIOL, V9, P576, DOI 10.1038/nrcardio.2012.109eng
hcfmusp.relation.referenceSalaroglio IC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0967-0eng
hcfmusp.relation.referenceSartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629eng
hcfmusp.relation.referenceSchett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7eng
hcfmusp.relation.referenceShin J, 2007, PHARMACOTHERAPY, V27, P874, DOI 10.1592/phco.27.6.874eng
hcfmusp.relation.referenceSiripanthong B, 2020, HEART RHYTHM, V17, P1463, DOI 10.1016/j.hrthm.2020.05.001eng
hcfmusp.relation.referenceSosa-Estani S, 2009, REV SOC BRAS MED TRO, V42, P484, DOI 10.1590/S0037-86822009000500002eng
hcfmusp.relation.referencede Sousa AS, 2008, ARQ BRAS CARDIOL, V91, P280eng
hcfmusp.relation.referenceda Silva GMS, 2018, J ANTIMICROB CHEMOTH, V73, P1115, DOI 10.1093/jac/dkx505eng
hcfmusp.relation.referenceTanowitz HB, 2015, EXPERT REV CARDIOVAS, V13, P1393, DOI 10.1586/14779072.2015.1103648eng
hcfmusp.relation.referenceTorreao JA, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0200-7eng
hcfmusp.relation.referenceUnited Nations, 2020, WORLD EC SIT PROSP Meng
hcfmusp.relation.referenceUniversity of California-San Francisco, 2019, INT AM ANTeng
hcfmusp.relation.referenceUrbina JA, 2009, MEM I OSWALDO CRUZ, V104, P311, DOI 10.1590/S0074-02762009000900041eng
hcfmusp.relation.referenceVerity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7eng
hcfmusp.relation.referenceViotti R, 2009, REV ESP CARDIOL, V62, P1224, DOI 10.1016/S0300-8932(09)73074-Xeng
hcfmusp.relation.referenceWang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585eng
hcfmusp.relation.referenceWHO, 2017, 4 WHO REP NEGL TROPeng
hcfmusp.relation.referenceWu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648eng
hcfmusp.relation.referenceZaidel EJ, 2020, MEDICINA-BUENOS AIRE, V80, P271eng
hcfmusp.relation.referenceZheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5eng
hcfmusp.relation.referenceZhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3eng
hcfmusp.relation.referenceZingone F, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30085-6eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication6d14d2a4-653a-4769-8c38-5a594ab3a09f
relation.isAuthorOfPublication.latestForDiscovery6d14d2a4-653a-4769-8c38-5a594ab3a09f
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_ZAIDEL_COVID19_Implications_for_People_with_Chagas_Disease_2020.PDF
Tamanho:
1.47 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/10